Skip to main content
SunVax mRNA Therapeutics

Put mRNA into the right place and the right cells.

SV-Delivery™ is a family of cell-type-specific lipid nanoparticle (LNP) kits for delivering mRNA, saRNA, and DNA — in vitro, ex vivo, and in vivo — without antibody conjugation. Pick the right kit, design your experiment, and troubleshoot — in minutes.

Find my kit in 5 minutes →Browse 13 products

Sources: SunVax conference presentation 2026-05-03 (slides 2-4). Every claim on this site is cited with an evidence grade (A/B/C). See about this site for our methodology.

Selected efficacy data A
  • Mouse CD4 T cells in vitro (SV101)94.1% GFP+
  • Mouse CD8 T cells in vitro (SV101)79.8% GFP+
  • Balb/c in vivo CD4 T (10 μg)52.2%
  • Balb/c in vivo CD8 T (10 μg)56.5%
  • Particle size (SV101/102/105/106)~80-100 nm
  • Freeze-thaw stability tested3 cycles
Source: SunVax conference 2026-05-03, slide 3 (in vitro & in vivo data).

What SV-Delivery™ offers

🎯

13 SV-Delivery™ kits

T cell, NK cell, B cell, monocyte/macrophage, HSC, and lymphatic targeting — for mouse and human. 6 listed, others under partnership development.

Browse the catalog →
🧪

Cell-type-specific tropism

Engineered via ionizable lipid chemistry — not antibody conjugation. SV101 achieves 94.1% in vitro CD4 T transfection with 4.34% CD19 B-cell off-target (selective).

How the kits are designed →
🤝

Research-grade + partnership

Buy listed kits directly from order.sunvaxmrna.com. For custom formulations or new cell-type targeting, contact the partnership team.

Partner with SunVax ↗

What we do not yet have

Honest disclosure is part of the methodology. The SV-Delivery™ platform is research-grade and still maturing. Specifically:

  • Human in vivo efficacy data is limited. PDX (patient-derived xenograft) experiments show 92-94% delivery efficacy, but the host is still an immunodeficient mouse — these results are not direct human in vivo evidence. A
  • Repeat dosing immunogenicity is not fully characterized. SunVax has run a small number of tests; complete dose-response and anti-capsid antibody data are still in progress. B
  • Most validation data uses mouse cytokine constructs. Human-construct preclinical testing is the necessary next step but is not yet complete. B
  • The platform is empirical, not ML-designed. SunVax explicitly uses an empirical screening + pattern-finding workflow — not machine learning or computational simulation. We don't market this site as "AI-driven design". A

Sources: SunVax conference 2026-05-03 (slides 3-4 and Q&A transcript Q1-Q5). All evidence grades are disclosed per claim. To request a correction, email yingzhongli@sunvaxmrna.com.

Four tools to get going

Built for wet-lab scientists, not procurement portals. Pick a kit, design an experiment, troubleshoot a failed run — sourced from public SunVax data, every claim with a citation.

1 · Kit selector

Three dropdowns → up to three SV-Delivery™ recommendations with match reasons and caveats.

2 · 13 product pages

Every kit: target cell, application, particle data, efficacy, dose, limitations, and source citations.

3 · Experiment designer

Pick a kit, set cell count, replicates, readout — get a downloadable bench protocol with controls.

4 · Troubleshooter

Decision tree for low transfection / cell death / no expression. Generates a diagnostic trace you can paste into a support email.